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Abstract
Background: Atherosclerosis is enhanced in arterial segments exposed to disturbed flow. Perturbed shear stress increases the expression of
oxidation-sensitive responsive genes (such as ELK-1 and p-CREB). Polyphenolic antioxidants contained in the juice derived from the
pomegranate contribute to the reduction of oxidative stress and atherogenesis during disturbed shear stress.
Aim of the study: To evaluate the effects of intervention with the Pomegranate Fruit Extract (PFE) rich in polyphones (punicalagin, which is
a potent antioxidant) on ELK-1, p-CREB, and endothelial nitric oxide synthase (eNOS) expression induced by high shear stress in vitro and
in vivo.
Results: At the doses used in the study, both the PFE and the regular pomegranate juice concentrate reduced the activation of ELK-1 and p-
CREB and increased eNOS expression (which was decreased by perturbed shear stress) in cultured human endothelial cells and in
atherosclerosis-prone areas of hypercholesterolemic mice. PFE and pomegranate juice increased cyclic GMP levels while there was no
significant effect of both compounds on the conversion of L-arginine to L-citrulline. Administration of these compounds to hypercho-
lesterolemic mice significantly reduced the progression of atherosclerosis and isoprostane levels and increased nitrates. This protective effect
was relevant with PFE. Vasomotor reactivity was improved and EC25 values in response to Ach and NONOate were significantly increased in
treated mice in comparison to controls.
Conclusion: This study indicates that the proatherogenic effects induced by perturbed shear stress can be also reversed by chronic
administration of PFE.
© 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
Keywords: Shear stress; eNOS; ELK-1; p-CREB; Pomegranate; Nitric oxide; Polyphenols; Antioxidants
1. Introduction
Vascular endothelial cells are exposed physiologically to
hemodynamic forces (regular laminar shear stress), which
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 stimulates the release of nitric oxide (NO) by constitutively
expressed endothelial NO synthase (eNOS) [1]. Perturbed
shear stress alone, or turbulent shear stress associated with
other classical risk factors of atherosclerosis, may trigger
signal transduction events that in turn may lead to endo-
thelial dysfunction and enhanced atherogenesis [2–4]. It has
been demonstrated that areas highly prone to atherogenesis
have unique patterns of disturbed flow, characterized by
regions of flow separation, recirculation, and spatial gra-
dients of shear stress [4]. Furthermore, vascular endothelial
cells under turbulent blood flow increase their production of
reactive oxygen species (ROS) and other free radicals that
are capable of inducing oxidative stress [5–12]. NO controls
vascular oxidative stress and the expression of redox-regu-
lated genes [13–15]. Evidence exists that eNOS activity is
reduced at sites of perturbed shear stress [2,5–8,11].
There is an abundant mythological history regarding the
pomegranate fruit which is detailed elsewhere [16–21].
The fruit of the pomegranate (about 50% of total pome-
granate weight) comprises 80% juice and 20% seeds; the
fresh juice contains 85% water, 10% total sugars, and 1.5%
pectin, ascorbic acid, and polyphenolic flavonoids [21].
The soluble polyphenol content varies within the limits of
0.2–1.0%, depending on variety, and includes mainly an-
thocyanins, catechins, ellagic tannins, and gallic and ella-
gic acids [17,18,21]. More importantly, pomegranate juice
possesses potent antioxidant activity that are associated to
its antiatherogenic properties in mice [21–23], and inhibi-
tion of cyclooxygenases and lipoxygenases [19]. Recently,
a novel Pomegranate Fruit Extract (PFE) rich in poly-
phones (punicalagin) was developed [24,25].
We have previously shown that intervention with anti-
oxidants and L-arginine reverses perturbed shear stress-
related redox gene activation and increases eNOS expression
both in cultured endothelial cells and in hypercholesterol-
emic mice [11]. The PFE, because of its robust content of
polyphenolic flavonoid antioxidants, is expected to enhance
the biological actions of naturally produced NO in vivo.
Regular pomegranate juice administered to hypertensive
patients caused a significant drop in blood pressure [26],a
reduction in carotid plaque development [27] and an im-
provement of stress-induced myocardial ischemia in patients
who have coronary heart disease [28]. From a pathogenic
point of view, we have shown that regular pomegranate juice
reduced the expression of oxidation-sensitive genes at the
sites of perturbed shear stress and protected against high-
prone atherosclerotic areas in hypercholesterolemic mice
[29].
Antioxidants are well known to enhance the biological
actions of NO by virtue of their capacity to stabilize NO by
protecting against the oxidative destruction of NO by ROS
and other radicals [13–15]. This antioxidant effect results in
much higher and more prolonged cellular concentrations of
NO, leading to markedly increased biological actions of NO.
In order to determine whether proatherogenic conditions
induced by turbulent shear stress can be attenuated also by
the PFE, we first studied cultured human coronary artery
endothelial cells subjected to high shear stress. The expe-
rimental protocols for this aim will be essentially the same as
those which we described [11,29]. We then analyzed high-
prone and low-prone atherosclerotic aortic areas and vas-
cular function of hypercholesterolemic mice after chronic
oral administration of PFE in comparison to regular pome-
granate juice.
2. Materials and methods
2.1. Pomegranate juice processing
Pomegranate juice concentrate (Wonderful variety, POM
Wonderful, LLC, Los Angeles, CA) and Pomegranate Fruit
Extract (Trademark POMx) were used in this study. Pome-
granates were handpicked, washed, chilled and stored in
tanks. The fruit was then crushed, squeezed, and treated
enzymatically to yield the juice and the Pomegranate Fruit
Extract. Pomegranate Fruit Extract includes not only juice
but also the inner and outer peels and the seeds of the
pomegranate. Flavonoids constitute 40% (anthocyanins,
catechins, and phenols) of total polyphenols in pomegranate
juice [20–22]. Both juices were filtered, pasteurized, con-
centrated, and stored at −20 °C until use. More details on
these compounds and preparation should be addressed to
www.pomwonderful.com.
2.2. Endothelial cell culture
Human coronary artery endothelial cells were cultured as
described previously [11,29–31]. Investigation was con-
formed with the principles outlined in the Declaration of
Helsinki for use of human tissue. Cells were incubated at
37 °C for 4 days in a humidified atmosphere of 95% air and
5% CO2. The incubation medium (delipidated DMEM) was
supplemented with 10 ng/ml human epidermal growth fac-
tor, penicillin/streptomycin, amphotericin B, and glutamine
[11,29–31]. All experiments were conducted between pas-
sages 3 and 5.
2.3. Flow apparatus for shear stress
Endothelial cells were subjected to laminar shear stress by
constant angular velocity in a cone-and-plate viscometer at a
relatively low level of 1 dyn/cm
3 (mean shear stress in
veins), at 5 dyn/cm
3, and at a higher level of 15 dyn/cm
3
(shear stress in arteries) one day after reaching confluence, as
described previously [11,29]. The viscometer consists of a
cone at a 0.5° angle rotating on top of a 94×16-mm cell
culture dish. Flow conditions achieved are considered lami-
nar because the parameter R (r2ωα2/12ν) was smaller than 4
(R1 and R15: 0.006 and 0.03 dyn/cm
2, respectively) [11,29].
On the basis of previous studies [21–23,25,29], endothelial
cells were exposed to different flows for 24 h in the absence
or presence of 7 or 14 μL both of regular pomegranate juice
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 and PFE (from 0.2 to 0.4 μmol total polyphenols). Both
compounds did not affect cell viability.
2.4. Determination of cGMPand NOSIII bioactivity
measurements
Endothelialcells(10
6cells)wereincubatedwith0.5mmol/L
isobutyl-1-methylxanthine and incubated with different treat-
ments for 24 h. The content of cGMP was measured using a
specific immunoreactivity kit (Amersham) according to the
manufacturer'srecommendations,asdescribed[32].Theeffect
ofdifferenttreatmentsonNOSIIImetabolismof[
3H]-arginine
to[
3H]-citrullinewasdeterminedusingstandardtechniques,as
described [32]. Cell lysates (150 to 250 μgo fp r o t e i n )w e r e
incubated with NADPH (2 mM), CaCl2 (230 μM), tetrahy-
drobiopterin (3 μM), and [
3H]-arginine (0.2 μCi, 10 μM) for
20 min at 37 °C.
2.5. Treatment of mice
This study was conducted according to the Guidelines for
Animal Experiments of the American Heart Association and
in accordance with the guidelines published by the National
Institutes of Health (NIH publication No. 85-23, revised
1985) and was approved by the institutional care of expe-
rimental committees. All efforts were made to minimize the
number of animals used and their suffering. Quality stan-
dards of Laboratories at the University of Naples (Italy) are
in accordance with rules establish from the Italian Ministry
of Health and the European College of Laboratory Animal
Medicine, while Laboratories of the Mayo Clinic at Roch-
ester (USA) and Universities of California at Los Angeles
are in accordance with the standards of the Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC). We used male hypercholesterolemic low-den-
sity-lipoprotein receptor-deficient (LDLR
−/−) mice (n=70,
mean weight 42.3±10.8 g, mean+SD) receiving a cholate-
free, high cholesterol diet (21% milk fat, 1.5% cholesterol
and 19.5% casein; #8137, Harlan/Teklad, Madison, WI), as
described [11,29,32,33]. This diet raised the mean plasma
cholesterol levels to about 900 mg/dL and plasma triglyc-
eride levels to 300 mg/dL. Some groups of mice will be
given the PFE in the drinking water for 1-month before the
disease is accelerated by a fatty diet, and then continued on
the juices of an additional 6-months. Of course, an appro-
priate controls will be run simultaneously with pomegranate
juice. Toassess whether pomegranate juice influenced stress-
responsive genes, mice were randomly divided into 5 groups
(n=14 each). Two groups of 3 month old mice received
regular pomegranate juice (high-dose and regular dose) in
the drinking water for 4 weeks before the disease was ac-
celerated by superimposing a fatty diet, and then continued
on the juice for an additional 24 weeks. The chosen doses of
regular pomegranate juice were based on previous studies
conducted in mice [21,22,29]. Concentrated pomegranate
juice or PFE were diluted in water (6.25 mL of concentrated
juice in 1 L of water). This solution was given to the treated
groups of mice, whereas only water was given to the placebo
control group of mice (Group 1). One group effectively
drank a mean of 30 μL of pomegranate juice/day (Group 2,
regular dose group), which is equivalent to 0.8 μmol of total
polyphenols/day [21,22,29] while the second group effec-
tively drank a mean of 50 μL of pomegranate juice/day
(Group 3, high-dose group). Similarly, another group effec-
tively drank a mean of 30 μL of PFE (Group 4, regular dose
group) while the second group effectively drank a mean of
50 μL of pomegranate juice/day (Group 5, high-dose group)
[24,25]. More details on the polyphenol contents of these
juices should be addressed to www.pomwonderful.com.
2.6. Blood determinations, preparation of arterial samples
and Western blot analysis
At the end of the treatment period, mice were euthanized
by CO2 asphyxia. Blood was drawn from the inferior vena
cava into heparinized tubes [11,29,33,34]. Plasma choles-
terol was determined enzymatically [29,33,34] and plasma
isoprostane 8-epi-PGF2α was determined using a commer-
ciallyavailableimmunoassay(CaymanChemical,AnnArbor,
MI), and nitrates (NOx levels) were measured with Griess
reagent (Calbiochem), as described previously [29,35–38].
The aorta was continuously immersed in PBS containing
10 μg/mL aprotinin and 0.1 mmol/L PMSF from the time
of the dissection until the computerized determination of the
atherosclerotic lesion area was completed [11,29,33–37].I m -
munostaining of macrophage-derived foam cells in paraffin-
embedded arterial sections was made using the F4/80 mo-
noclonal antibody (Serotec, dilution 1:250) against mouse
foam cells [11,29,33–37], while oxidation-specific epitopes
were identified by using the MDA-2 monoclonal antibody
[29,35,36]. Intercellular junctions were stained with 0.25%
silver nitrate to visualize the endothelium in the high-prone
andlow-proneatheroscleroticaorticregions(locatedmainlyin
the proximal aorta), as described [11,29,36,39]. Tissue sec-
tions (5 μm) from the different arterial regions were homoge-
nized in 250 μL of protein extraction buffer for determination
of protein content by Western blot as described in detail
[20,22,29,36]. We used the following monoclonal antibodies:
ELK-1 (I-20, goat antibody), p-CREB (Sc:7978), and eNOS
III (N-20, epitope corresponding to an amino acid sequence
mapping at the amino terminus of NOS-III, no cross reactivity
with NOS-I or NOS-II, neuronal and inducible forms, res-
pectively) purchased from Santa Cruz Biotechnology (San
Diego,CA)[11,29].Semiquantitative densitometryofWestern
blots was performed using a Scan LKB (Pharmacia-Sweden)
[11,29–37].
2.7. Vasomotor reactivity
Endothelial function was studied by using endothelial
rings (a term usually referred to pieces of arteries placed in a
bath) [40]. In a subset of hypercholesterolemic mice, carotid
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 arteries were studied using a microcannula, as described [41].
Arteries were dissected, connective tissue was removed under
a microscope (Carl Zeiss; Germany) and placed immediately
in ice-cold modified Krebs-Ringer solution [40,41].B r i e f l y ,
artery was placed in a vessel chamber (Living Systems Ins-
trumentation; Burlington, VT) filled with aerated (94% O2–
6%CO2)Krebs-Ringersolutionat37°C,whichflowedfroma
250-ml reservoir to the chamber at a rate of 50 ml/min. A
pressure of 50 mmHg was maintained through the micro-
cannula. Arteries were submaximally contracted with the
thromboxane analog 9,11-dideoxy-11,9-epoxy-methanopros-
taglandin F2 (U-46619, 10
−7 to 10
−6 M), and endothelium-
dependent relaxation was then obtained using acetylcholine
(Ach, 10
−9 to 10
−5 M). After washout, equilibration, and sub-
maximal contraction of the arteries with U-46619, endo-
thelium-independent relations were determined using
diethylammonium (Z)-1-(N,N-diethylamino)diazen-1-ium-
1,2-diolate (DEA-NONOate, 10
−9 to 10
−5 M). ACh hydro-
chloride was obtained from Sigma Chemical (St. Louis, MO).
DEA-NONOate and U-46619 were from Cayman Chemical
(Ann Arbor, MI). In a parallel protocol, arteries were prein-
cubated with 10
−5 Mo fP J( n=6 )o rP F E( n=6) for 20 min
before contraction.
2.8. Statistical analysis
All data are reported as means±SE or SD. SigmaStat was
used to perform all statistical analyses, which were preceded
by a test for normality. For comparison between two groups,
Mann-Whitney tests or t tests were performed where needed.
Dose-responsecurveswerecomparedusingtwo-wayANOVA
for repeated measures. Comparisons of multiple groups were
made using a one-way ANOVA by two independent inves-
tigatorsinablindedfashion.AllANOVAswerefollowedwith
Bonferroni's correction. Pb0.05 was considered significant.
3. Results
3.1. Effects of PFE and pomegranate juice in cultured
endothelial cells
As expected from previous findings [11,29], basal eNOS
activity was increased by approximately 50% at 1 dyn/cm
2
shear stress, but only 15% at 15 dyn/cm
2 shear stress
(Densitometric analysis is quantified in Table 1). After
concomitant cell exposure to 7 μL of regular pomegranate
juice or PFE, eNOS activity showed a significant further
Table 1
Effects of PFE or regular pomegranate juice (PJ) in cultured human coronary artery endothelial cells (EC) exposed to shear stress generated in vitro (0, 1, 5 and
15 dyn per cm
2) on endothelial nitric oxide synthase (e-NOS), ELK-1, and phosphorylated form of CREB (p-CREB) protein levels measured by Western Blot
Control PJ 7 μLP J 1 4 μL
0 1 dyn 5 dyn 5 dyn 0 1 dyn 5 dyn 15 dyn 0 1 dyn 5 dyn 15 dyn
eNOS 2.1±0.3 3.0±0.4⁎ 2.5±0.5 2.3±0.4 2.2±0.4 3.3±0.5# 3.1±0.5# 2.8±0.4# 2.3±0.5 4.1±0.5⁎⁎ 3.2±0.6⁎⁎ 3.2±0.5⁎⁎
ELK-1 2.0±0.3 3.2±0.4 4.0±0.5§ 5.0±0.5§ 2.0±0.3 2.5±0.4# 3.0±0.5# 3.9±0.4# 1.9±0.4 2.4±0.4⁎⁎ 2.8±0.5⁎⁎ 3.3±0.5⁎⁎
p-CREB 2.0±0.4 2.4±0.3 2.8±0.3⁎ 3.0±0.4⁎ 1.9±0.2 2.1±0.2 1.8±0.4# 2.2±0.3# 1.7±0.3 1.9±0.4# 1.6±0.4# 1.8+0.3#
PFE 7 μL PFE 14 μL
0 1 dyn 5 dyn 15 dyn 0 1 dyn 5 dyn 15 dyn
eNOS 2.4±0.5 3.4±0.5# 3.2±0.5# 2.9±0.5# 2.5±0.5 4.4±0.5⁎⁎,° 3.6±0.6⁎⁎,° 3.6±0.5⁎⁎,°
ELK-1 2.1±0.3 2.6±0.4# 3.0±0.6# 4.0±0.4# 1.9±0.4 2.2±0.3⁎⁎ 2.4±0.4⁎⁎,° 2.5±0.4⁎⁎,°
p-CREB 1.9±0.2 2.1±0.4 1.5±0.4# 2.0±0.4# 1.8±0.3 1.5±0.4⁎⁎,° 1.2±0.4⁎⁎,° 1.5±0.4⁎⁎,°
Legend: Control untreated EC or EC treated with PFE or PJ diluted in the cellular medium were exposed to shear stress for 24 h. Densitometric analysis of blots
normalized with γ-tubulin are representative of the mean±SD of 6 different experiments. p, significance by Bonferroni's corrected t test.⁎pb0.05 vs. 0 dyn;
#pb0.05 vs. respective force in Control untreated cells;⁎⁎pb0.01 vs. respective force in Control untreated cells; §pb0.001 vs. 0 dyn; °pb0.05 vs. respective
dose of PJ.
Table 2
Cyclic guanosine monophosphate (cGMP) levels and endothelial nitric oxide synthase (eNOS) activity measured by monitoring the conversion of L-arginine to
L-citrulline in human endothelial cells exposed to shear stress and treatments
Control PJ 14 μL PFE 14 μL
0 1 dyn 5 dyn 15 dyn 0 1 dyn 5 dyn 15 dyn 0 1 dyn 5 dyn 15 dyn
cyclic GMP
(mol/μg) 6.1±1.2 8.2±2.1⁎ 6.5±1.4 6.4±1.6 6.2±1.3 9.8±2.3⁎ 8.0±2.1⁎ 7.6±1.5⁎ 6.5±1.8 10.2±2.6⁎,# 8.4±1.6⁎ 8.2±1.5⁎
NOS activity
(% of control) 95±36 92±28 90±25 88±35 92±34 90±29 90±27 87±30 93±30 91±25 89±28 90±31
Legend: Control untreated EC or EC treated with PFE or PJ diluted in the cellular medium were exposed to shear stress for 24 h. Data are representative of the
mean±SD of 3 different experiments.⁎pb0.05 vs. 0 dyn; #pb0.05 vs. respective force in Control untreated cells.
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 increase at all levels of shear stress (Table 1). These effects
were concentration-dependent since cell exposure to 14 μL
of both juices induced further increments of eNOS activity
(Table 1). However, at this higher dose, PFE was more
efficient in enhancing eNOS expression than regular pome-
granate juice. Shear stress also increases oxidation-sensitive
ELK-1 expression [11,29]. Treatment with 7 μL of regular
pomegranate juice or significantly attenuated the increase in
ELK-1 protein levels compared to the untreated control at the
same flow or shear stress (Table 1). Again, treatment with
14 μL of both juices further decreased ELK-1 expression
(Table 1). Also in this case, PFE was more potent than
regular pomegranate juice. Comparable results were ob-
tained for p-CREB (Table 1). PFE and pomegranate juice
increased cyclic GMP while there was no significant effects
of both compounds on eNOS activity measured as the con-
version of L-arginine to L-citrulline (Table 2).
3.2. Effects of PFE and pomegranate juices in
hypercholesterolemic mice
Plasmacholesterol levelswerenot significantlyaffectedby
pomegranate juice or PFE consumption (882±66, 875± 69,
Fig. 1. Effects of regular (rd) and high-doses (hd) of PFE and pomegranate
juice (PJ) or placebo on atherosclerosis progression (Panel A), macrophage
accumulation (F4/80 antibody, Panel B), and oxidation-specific epitopes
(MDA-2 antibody, Panel C) in hypercholesterolemic mice fed high-fat diet.
HV, healthy vessel areas; LP, low-prone atherosclerotic areas; HP, high-
prone atherosclerotic areas; rD, regular dose; hD, high-dose. Atherosclerotic
lesion area and both the number of F4/80 and MDA-2 positive arterial
section were assessed by computer-assisted imaging analysis as described in
methods. Mean±SD; p, significance by Bonferroni's corrected t test.
⁎pb0.05 vs. placebo control group of mice; ⁎⁎pb0.01 vs. placebo control
group of mice; §pb0.05 vs. respective PJ-treated group; °pb0.01 vs.
respective PJ-treated group.
Fig. 2. Effects of pomegranate juice (PJ rd in b; PJ hd in c) and Pomegranate
Fruit Extract (PFE rd in d; PJ hd in e) on aortic atherosclerotic lesion areas in
hypercholesterolemic mice. Comparison of the extent of lipid staining by oil
red O in representative sections of the aorta of a placebo-treated control
mouse (a). Cryosections 10 μm thick were stained with oil red O, and
counterstained with hematoxylin. Immunohistochemical staining of aortic
sections for macrophages of a placebo-treated control mouse (f), in a PJ-rd-
treated mouse (g) or PJ-hd-treated mouse (h), PFE-rd-treated mouse (i) or
PFE-hd-treated mouse (L). Finally. immunohistochemical staining of aortic
sections for oxidation-specific epitopes (MDA-2 monoclonal antibody).
Placebo-treated control mouse (m), PJ-rd-treated mouse (n), PJ-hd-treated
mouse (o), PFE-rd-treated mouse (p) or PFE-hd-treated mouse (q). See
Methods for more technical details. All figures are 125×.
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 and 865±70 mg/dL in the placebo-treated, high-dose pome-
granate juice-treated mice, and high-dose PFE, respectively).
Plasma isoprostanes in mice treated with both juices were
reduced compared to placebo-treated mice (109±18⁎,1 0 2 ±
20⁎ vs. 145±32 pg/ml, high-dose pomegranate juice, high-
dose PFE and placebo-treated mice, respectively, ⁎pb 0.03
vs. placebo group). Note that isoprostanes were also reduced
in the regular dose pomegranate juice-treated groups of mice
(119±21⁎) as well as in the regular dose PFE-treated group
(115±24⁎; ⁎pb0.05 vs. placebo group). Accordingly, plas-
ma NOx increased in mice treated with both juices in com-
parison to placebo-treated mice (26±3⁎,2 9 ±4 ⁎ vs. 18±
2 μm, high-dose pomegranate juice, high-dose PFE and
placebo-treated mice, respectively, ⁎pb0.05 vs. placebo
group). As expected [29], atherosclerotic lesions in low-
prone and high-prone areas of placebo groups of mice were
larger than those observed in treated groups of mice in both
protocol doses, and consisted of many more lipid-laden
macrophage foam cells (F4/80 immunostaining) and oxi-
dation-specific epitopes (MDA-2 immunostaining) (Figs. 1
Fig. 3. Representative analysis of effect of shear stress (15 dyn per cm
2)o n
eNOS protein levels measured by Western blot in mice receiving placebo, PJ
high-dose or PFE high-dose. Lanes 1, 4, 7 are placebo-treated mice in HV,
LP and HP areas, respectively, lanes 2, 5 and 8 are PJ-hd-treated mice in HV,
LP and HP areas, respectively, and, finally, lanes 3,6,9 are PFE-hd-treated
mice in HV, LP and HP areas. ⁎pb0.05 vs. placebo control group of mice;
§pb0.05 vs. respective PJ-treated group.
Table 3
Effects of PFE or regular pomegranate juice (PJ) on eNOS expression and shear stress-responsive genes (ELK-1 and p-CREB) in hypercholesterolemic mice fed
high-fat diet in the study protocol
Placebo group (n=14) PJ rD group(n=14)
HV LP HP HV LP HP
eNOS 3.3±0.4 2.5±0.5 1.8±0.3 3.4±0.4 3.2±0.4⁎⁎ 2.6±0.2⁎⁎
ELK-1 1.1±0.3 2.0±0.4 3.1±0.5 1.0±0.2 1.6±0.4⁎ 2.4±0.4⁎
p-CREB 1.5±0.4 2.2±0.3 3.0±0.4 1.2±0.2 1.6±0.4⁎ 2.3±0.4⁎
PJ hD group (n=14) PFE rD group (n=14)
HV LP HP HV LP HP
eNOS 3.5±0.4 3.3±0.4⁎⁎ 2.7±0.2⁎⁎ 3.4±0.4 3.5±0.4⁎⁎ 2.8±0.2⁎⁎
ELK-1 1.0±0.2 1.5±0.4⁎ 2.2±0.4⁎⁎ 1.0±0.2 1.4±0.4⁎ 2.3±0.4⁎
p-CREB 1.4±0.4 1.5±0.4⁎ 2.0±0.3⁎ 1.3±0.4 1.5±0.4⁎ 2.1±0.5⁎
PFE hD group (n=14)
HV LP HP
eNOS 3.4±0.4 4.0±0.5⁎⁎,§ 3.0±0.4⁎⁎,§
ELK-1 1.0±0.2 1.3±0.4⁎⁎ 2.0±0.4⁎⁎,§
p-CREB 1.4±0.4 1.3±0.3⁎⁎ 1.8±0.3⁎⁎
Legend: HV, healthy vessel areas; LP, low-prone atherosclerotic areas; HP, high-prone atherosclerotic areas; rD, regular dose; hD, high-dose. Densitometric
analysis of Western blots normalized with γ-tubulin are representative of the mean±SD of each mouse in study groups. p, significance by Bonferroni's corrected
t test.⁎pb0.05 vs. placebo control group of mice;⁎⁎pb0.01 vs. placebo control group of mice; §pb0.05 vs. respective PJ-treated group.
Table 4
Vasomotor reactivity parameters in carotid arteries segments
Control PJ PFE
Basal Diameter(μM) 412±10.4 413±8.2⁎ 412±10.2
Diameter of contraction to U46619
(μM)
175±12 173±14⁎ 176±15⁎
Maximum Relaxation
To Ach (%) 57±12 72±11⁎ 74±14
To DEA-NONOate (%) 58±11 84±12⁎ 87±13⁎
EC25-Log M
To Ach 6.85±0.15 7.56±0.16⁎ 7.65±0.15⁎
To DEA-NONOate 6.66±0.14 7.22±0.09⁎ 7.27±0.12⁎
Legend: Data are representative of the mean±SE; n=6 mice per group.
⁎pb0.05 vs. Control untreated cells. U-46619, 9,11-dideoxy-11-9-epox-
ymethanoprostaglandin F2; Ach, acetylcholine; DEA-NONOate, diethylam-
monium-(Z)-1-(N,N-diethylamino)diazen-1-inm-1,2-diolate.
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 and 2). There was approximately a 25% decrease in both
lesion area and foam cell formation in pomegranate-treated
mice. These antiatherogenic properties of regular pome-
granate juice were consistent with previous findings from
t h eA v i r a m ' sg r o u p[21–23]. More importantly, the treat-
ment with PFE induced a more significant reduction of
atherosclerotic lesion development (around 40%) than that
achieved with regular pomegranate juice (Fig. 1,P a n e lA ) .
When consideringperturbed shear stress-related areas, the
artery can be visualized as possessing healthy vessel areas,
and low-prone and high-prone-atherosclerotic areas [11,29].
Densitometric analysis of Western blots showed that in
comparison to healthy vessel areas, basal eNOS activity
before treatment was decreased by about 25% and 45% in
low-prone and high-prone areas, respectively (Fig. 3 and
Table 3). After regular pomegranate juice administration,
eNOS activity increased significantly both in low-prone and
high-prone areas; this phenomenon was more evident when
PFE was used (Table 3). As expected [11,29], ELK-1 was
increased significantly in low-prone and in high-prone areas
in control mice; comparable results were obtained for p-
CREB (Table 2). After regular pomegranate juice treatment,
ELK-1 and p-CREB protein levels were significantly dec-
reased in low-prone and high-prone areas (Table 3). This
beneficial effect was more pronounced when PFE was
administered to mice (Table 3). Thus, therapeutic beneficial
effects (e.g., increasing eNOS and decreasing redox gene
expression in perturbed shear stress areas) were elicited both
by PFE and pomegranate juices during chronic intervention.
When considered vasomotor reactivity, there was a
significant maximum relaxation to Ach and DEA-NONOate
in arteries exposed to PFE (Table 4). Moreover, the EC25
values of arteries in response to both ACh and DEA-
NONOate were significantly increased with both pomegra-
nate juice and PFE (Table 4). There was no difference
observed between groups when considered diameter of con-
traction to U46619 (Table 4).
4. Discussion
The present study shows that prolonged supplementation
with PFE or regular pomegranate juice can largely correct
the perturbed shear stress-induced proatherogenic disequi-
librium by increasing eNOS activity (and cGMP) and dec-
reasing redox-sensitive transcription factors both in vitro in
cultured human coronary endothelial cells and in vivo in
hypercholesterolemic mice. The degree of potency of PFE
was significant higher than that of pomegranate juice. The
hypercholesterolemic mice spontaneously develop athero-
sclerosis, which can be accelerated by feeding the mice a diet
rich in fats [11,29,33–37]. Accordingly, the purpose of this
study was to determine whether PFE, like other natural
sources of antioxidants and pomegranate juice, reduces oxi-
dative stress, oxidation-specific epitopes and atherogenesis
in arteries from hypercholesterolemic mice. Vascular dis-
orders such as atherosclerosis cause disturbed blood flow in
the affected regions and this leads to perturbed shear stress
that, in turn, causes endothelial damage. Moreover, endo-
thelial dysfunction is attributed to increased oxidative stress
and decreased NO production and action [12–15]. Thus, the
protective effects of NO in the vasculature are lost and
atherosclerosis develops as a result. Administration of anti-
oxidants in experimental models has been shown to reduce
the severity of atherosclerosis by reducing oxidative stress
and increasing NO production and action [14,42]. In the
present study, PFE and pomegranate juice supplementation
to LDLR
−/−mice, which are under oxidative stress, resulted
in substantially lower plasma lipid peroxidation (assessed by
plasma isoprostanes) and higher plasma nitrates than in
control mice. Reductions in macrophage foam cell forma-
tion, oxidation-specific epitopes and lesion area in athero-
sclerotic prone lesion regions (low-prone and high-prone
areas)bothinPFEandregular pomegranate juice-treatedmice
clearly confirm the correlation between antioxidative effects
and their antiatherogenic properties, as was observed in other
studies [21–23,25]. Moreover,wehaveshown thatvasomotor
reactivity (EC25 of relaxation in response to Ach and NONO
ate) was improved with both treatments. Thus, it was im-
proved both endothelium-dependent (Ach) and -independent
relaxation induced by NONOate.
The second aim of the present study was to determine the
possible beneficial effects of PFE and pomegranate juice on
oxidation-sensitive gene expression, and eNOS at sites of
disturbed shear stress. The present study confirmed that
modulation of ELK-1, p-CREB and eNOS expression (and
cGMP levels in cells) is associated with antiatherogenic
activity in such areas. These effects are similar to those
elicited by antioxidants (vitamin E and C) and L-arginine
[11]. However, PFE and pomegranate juice did not appre-
ciably inhibit eNOS activity at dilutions that exhibited vas-
cular protective effects. Thus, these compounds did not
influence eNOS catalytic activity. Polyphenols are the most
abundant antioxidants in our diets. The main classes of
polyphenols are phenolic acids (mainly caffeic acid) and
flavonoids (the most abundant in the diet are flavanols
(catechins plus proanthocyanidins), anthocyanins and their
oxidation products), which account for one- and two-thirds,
respectively [43]. Polyphenols are reducing agents that may
protect the body's tissues against oxidative stress and asso-
ciated pathologies such as cancer, cardiovascular diseases
and inflammation [43,44]. It is important to understand the
nature of the main polyphenols ingested, their dietary origin,
the amounts consumed in different diets, their bioavailabil-
ity and the factors controlling their bioavailability. Pome-
granate juice and PFE are rich in antioxidants of the
polyphenolic class, which includes tannins and anthocyanins
[19,22–24]. These antioxidants are more potent, on a molar
basis, than many other antioxidants including vitamin C,
vitamin E, coenzyme Q-10 and alpha-lipoic acid [19–22,24].
The antioxidant level in pomegranate juice was found to be
higher than that in other natural juices such as blueberry,
cranberry and orange, as well as red wine [24,45]. The
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 development of PFE further increases the content of
punicalagin [24,25].
Polyphenols from red wine can reduce LDL aggregation
in vitro and in vivo and caused alone an upregulation of
eNOS expression and NO formation [45–47], and regular
pomegranate juice administered to cardiovascular patients
ameliorate blood pressure and myocardial perfusion [26–
28]. Moreover, regular pomegranate juice consumption for
3 years by patients with carotid artery stenosis reduced
common carotid intima-media thickness, blood pressure and
LDL oxidation [27]. Accordingly, an early study showed that
tea-pigment (and possibly polyphenols) exerted some anti-
atherosclerotic effects [48]. Short- and long-term black tea
consumption reverses endothelial dysfunction in patients
with chronic heart disease [49]. Similarly, the ingestion of
polyphenols contained in purple grape juice had beneficial
effects on endothelial function in patients with coronary
heart disease [50]. Taken together, these data suggest that
polyphenols can protect arteries from vascular damage via
antioxidant effects and NO restoration. However, certain
largeclinicaltrialsemployingdifferentantioxidantshavefailed
to show any beneficial effects in terms of prevention of major
cardiovascular events [5,12,14,42]. One possible explanation
ofthis divergenceisthatthe models employed in experimental
studies, although very useful to study pathophysiological
mechanisms,maynotprecisely reflectthedisease inhumans
[5,12,14,42]. Alternatively, the doses of antioxidants used
in those few studies may not have been appropriate, and/
or the progression of disease may have been too severe.
Finally, it was proposed that pomegranate juice can be used
also in the chemoprevention of prostate cancer [51] and
exerted beneficial effects during chronic obstructive pulmo-
nary disease [52].
The data in the present study show that elevation of the
redox factors ELK-1 (a ternary complex factor of the Ets
family) and p-CREB, which are associated with perturbed
shear stress [11,29], can be reversed by the intervention with
PFE or regular pomegranate juice in cultured human coro-
nary artery endothelial cells and in hypercholesterolemic
mice. Indeed, eNOS, p-CREB and ELK-1 are “primed” to
respond to systemic activation stimuli in high-prone versus
low-prone areas that represent areas with most and least
atherosclerosis in mice and pigs. Using PFE or pomegranate
juice therapeutic intervention, we demonstrate that it is
possible to attenuate this proatherogenic scenario. Antiox-
idant protection elicits decreased cellular production and
release of oxygen radicals in the vascular wall, inhibits
endothelial activation of oxidation-sensitive genes, improves
the biologic activity of NO through a cell- or tissue-specific
antioxidant action [14,53] and upregulates eNOS expression
in the presence of oxidized low-density-lipoprotein [54].
Very recent data shows that pomegranate juice protects NO
against oxidative destruction in bovine pulmonary artery
endothelial cells [55].
In summary, therapeutic intervention with antioxidant
polyphenols contained in PFE and regular pomegranate juice
may promote a sustained correction of the perturbed shear
stress-induced proatherogenic profile in vitro and in vivo
with atherosclerosis reduction and improvement of vascular
function. These findings may have nutritional implications
for the prevention of atherogenesis.
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